GB1603772A – Antibody immobilized in a acrylamide copolymer matrix
– Google Patents
GB1603772A – Antibody immobilized in a acrylamide copolymer matrix
– Google Patents
Antibody immobilized in a acrylamide copolymer matrix
Download PDF
Info
Publication number
GB1603772A
GB1603772A
GB16822/78A
GB1682278A
GB1603772A
GB 1603772 A
GB1603772 A
GB 1603772A
GB 16822/78 A
GB16822/78 A
GB 16822/78A
GB 1682278 A
GB1682278 A
GB 1682278A
GB 1603772 A
GB1603772 A
GB 1603772A
Authority
GB
United Kingdom
Prior art keywords
acrylamide
antibody
immobilised
copolymer
polymer matrix
Prior art date
1977-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB16822/78A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chandon Investment Planning Ltd
Original Assignee
Chandon Investment Planning Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1977-05-11
Filing date
1978-04-27
Publication date
1981-11-25
1978-04-27
Application filed by Chandon Investment Planning Ltd
filed
Critical
Chandon Investment Planning Ltd
1981-11-25
Publication of GB1603772A
publication
Critical
patent/GB1603772A/en
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
G01N33/545—Synthetic resin
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K39/44—Antibodies bound to carriers
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S436/00—Chemistry: analytical and immunological testing
Y10S436/807—Apparatus included in process claim, e.g. physical support structures
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S436/00—Chemistry: analytical and immunological testing
Y10S436/815—Test for named compound or class of compounds
Y10S436/817—Steroids or hormones
Description
PATENT SPECIFICATION ( 11)
: ( 21) Application No 16822/78 ( 22) Filed 27 April 1978 t ( 31) Convention Application No 2 721 267 ( 15 ( 32) Filed 11 May 1977 in : ( 33) Fed Rep of Germany (DE) : ( 44) Complete Specification published 25 Nov 1981 ( 51) INT CL 2 CO 7 C 7/00//GOIN 33/54.
( 52) Index at acceptance C 3 H 200 220 230 241 250 HI GIB BR ( 54) ANTIBODY IMMOBILIZED IN A ACRYLAMIDE COPOLYMER MATRIX 1603772 ( 71) We, CHANDON INVESTMENT PLANNING LTD, a company organised under the laws of the Cavman Islands (British West Indies), of West Wind Building, P O B 1 X 1 Grand Cayman, Cayman Island, British West Indies, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:-
The invention relates to antibodies immobilised in a polymer matrix based on acrylamide for use, in particular, in the radioimmunological determination of hormones, pharmaceuticals and vitamins.
In the radioimmunological determination of hormones, pharmaceuticals and vitamins, the hormones, pharmaceuticals or vitamins react with an antibody The specificity of the reaction depends on immunological complementing, i e, a cross reactivity may exist with substances exhibiting a similar chemical configuration In an estriol-C 6 conjugate, the > 5 esteriol is present in an immunodeterminate configuration, in which nearly all of the important functional groups of the esteriol are exposed to the bonding range of the antibody.
In spite of this, esteriol conjugates with the 0 sulfate or glucuronide residue occupying the position at the phenolic CQ are bonded to a considerable degree by the antibody This is disadvantageous for the determination of free steroids, especially if the conjugate concentration exceeds the steroid concentration by orders of magnitude, as is true for the estrogens in the serum of pregnant women.
For these reasons heretofore, methods were essentially used in which specificity was ensured by solvent extraction prior to the radioimmune assay Solvent extraction interferes, however, with continuous and mechanised sample processing.
In experiments to simplify radioimmunological methods by way of solid phase techniques, antibodies were bonded covalently to different matrices, e g, agar, cellulose, glass particles, polyamides and polyacrylamides; see for example United States Patent No.
3,793,445 to Updike et al The advantages of antibodies enclosed in a matrix consist of the exclusion of interfering molecules of higher molecular weight, the savings of pipetting and centrifuging and the extended stability of the immobilised antibodies at room temperature.
It has been found that the bonding specificity of the antibody, when immobilised in the known manner in a matrix, does not satisfy desirable requirements.
It has been found surprisingly that a variation and increase in bonding specificity of the antibody thus preventing the occurrence of undesirable cross reactions can be obtained through the use of polymer matrices of certain copolymers of acrylamide According to the present invention there is provided an antibody immobilised in a polymer matrix which comprises a matrix of acrylamide copolymer and an antibody immobilised in the matrix, the acrylamide copolymer being a copolymer of acrylamide and at least one monomer chosen from acrylic acid, methacrylic acid, methacrylamide, salts and esters of acrylic acid or methacrylic acid, acrylamide or methacrylamide substituted at the nitrogen atom, and N,N’-dialkyltartardiamides.
With the aid of the immobilised antibodies of the invention, highly accurate, in particular radioimmunological, determinations of hormones, pharmaceuticals and vitamins are possible, because the fluctuation of the values determined attributable to non-specific bonds between steroid molecules and the matrix is minimised by the copolymerisation.
The micro-environment of the polymer matrix is affected by the copolymerisation of acrylamide with the comonomer The hydrophobic and hydrophilic effects and electrostatic effects within the polymer matrix are found to be dependent upon the acrylamide copolymer and provide the particularly desirable bonding specificity By varying the polymer matrix through copolymerisation, it is possible to achieve a substantial increase in the bond1,603,772 ing specificity of the antibody and to suppress undesirable cross activities The polymer matrix is varied through a suitable copolymerisation in order to assure a specific reaction of haptens with the immobilised antibody and to prevent the cross section of haptens Because of the increased specificity, the polymer matrices of the invention permit measurements directly in the non-extracted serum.
In various determinations, such as, e g, of the thyroid hormones, thyroxine and tri-iodothyronine, competitive substances are used, such as anilinenaphtholsulfonic acid, merthoilate or salicylate, in order to displace the hormones from their bond with the different bonding proteins in the serum It is known, however, that in the case of higher concentrations of these competitive substances, the bond between the hormone and the antibody is affected With the use of the immobilised antibodies of the invention, it is possible to substantially increase the concentration of the competitive substances, i e by a factor of 100, without weakening the hormone-antibody bond Without fully stating the reason for this result, it is presumed that electrostatic interactions are responsible.
The immobilised antibodies of the present invention may in particular be used in the determination methods described and claimed in our copending Applications Nos 16823/78 and 16824/78 (Serial Nos 1603773 and 1603774).
The acrylamide copolymer of the present invention may be prepared according to known procedures for polymerizing acrylamide monomer and copolymerizable monomers.
Formation of the desired copolymer matrix arrangement is described in greater detail hereinafter.
The proportion of acrylamide in the copolymer may be from 1 to 99 mole%, preferably from 5 to 95 mole% and, most preferably, from 20 to 80 mole% Especially suitable are copolymers of acrylamide and methacrylic acid and, more particularly, those in which the proportion of methacrylic acid is 20 to 60 mole% based on the acrylamide.
Methacrylic acid yields a hydrophobic matrix and provides a charge effect, permitting the extensive elimination of non-specific bonds of the substances to be determined.
Through the use of copolymers in accordance with the invention containing acrylic acid or methacrylic acid or salts thereof, a neutralization effect or a buffering action can be achieved for acid or alkaline solutions This is a significant advantage in numerous determinations.
The preferred salts of acrylic acid or methacrylic acid are alkali metal or alkaline earth metal salts Sodium and potassium salts are particularly preferred.
The preferred esters of acrylic acid or methacrylic acid are the methyl and ethyl esters.
The methacrylamide substituted at the nitrogen atom may be for example Nhydroxymethylmethacrylamide.
There may also be used, as comonomer with acrylamide, NN’-dialkyltartardiamide.
The immobilization of the antibody takes place through inclusion in the polymer matrix and/or through covalent fixation in the polymer matrix in a known manner A detailed description of the radioimmune assay is found, for example, in Clinical Chemistry, Vol 19, No 2, 1973, p 145 In Clinical Chemistry, Vol 19, No 12, 1973, p 1339, and Clinical Chemistry, Vol 21, No 7, 1975, p 829, radioimmunological techniques are described in which immobilized antibodies are used.
The immobilized antibodies of the invention are suitable for the determination of different hormones, pharmaceuticals and vitamins, which are present in the serum or the plasma bonded in part to specific or nonspecific bonding proteins The hormones may consist of thyroid hormones, particularly thyroxine and tri-iodothyronine, the steroid hormones, such as cortisol, testosterone, progesterone, estron, estradiol and estriol and the heart glycosides, such as digitoxin and digoxin Vitamins, particularly, Vitamin B 12 and folic acid, also pharmaceuticals with strong protein bonds, such as, for example, anti-coagulants, dicumarol, analgesics and salicylates, may further be determined.
In addition to radioimmunological determinations, alternative methods of determination, such as, fluoroimmunological determinanation or determination with enzymatic marking, may also be considered.
The synthesis of antigens, the production of antisera, for example through the immunisation of anti-bodies, are known (see for example, Clinical Chemistry, Vol 19, No 2, 1973, p 146 ff).
The preparation of the antibody immobilized in a polymer matrix according to the invention may take place, for example, by adding a solution of the antibody to the monomer mixture The initial mixture is, for example, polymerized by free radical polymerization and the polymer obtained comminuted, washed and dried.
The selection and the proportions of the copolymers added to the acrylamide are determined by the properties of the polymer desired with respect to specificity The specificity may be varied over a wide range by altering the hydrophobicity and the charge of the matrix The addition of the methylacrylamide increases hydrophobicity The addition of acrylic acid or methacrylic acid or salts thereof varies the charge of the matrix It is possible, both to add the salts of acrylic acid or methacrylic acid directly to 1,60 G 3,772 the monomer mixture or alternatively to polymerize the acids and subsequently form the salts in the polymer matrix through the exchange of ions.
The monomer concentration in the starting solution may be varied to obtain a suitable pore size of the polymer matrix A monomer concentration in the range of approximately mole% results in a pore size of approxil O mately 7 to 10 A.
An advantageous copolymer consists, for example, of acrylamide and 20 to 60 mole/%, based on the acrylamide, acrylic acid and/or methacrylic acid, prepared from an approximately 20 mole /0 monomer solution, where at least part of the acid groups are converted into the corresponding alkali metal or alkaline earth metal salts.
The invention will now be explained in more detail with the aid of Examples.
Example 1.
In this Example, the effect of the use, as polymer matrix, of acrylamide homopolymer and acrylamide copolymer according to the invention on the cross reactivity (K) of estr;ol-3-glucoronide and estriol-3-sulfate is compared.
i ne antiestriol antibody chosen displays high cross reactivity of the 3-glucuronide 0 conjugate and the 3-sulfate conjugate.
For each polymerisation mixture, the concentration was adjusted so that the total monomer concentration amounted to 2 9 mole%.
For one mixture, for example, 5 g acrylamide and 1 25 g N,N’-methylenebisacrylamide were dissolved in a glass beaker in 24 ml of a phosphate buffer with a p H value of 7 2 After the addition of the antibody in 0 1 ml phosphate buffer, the reaction was initiated with 0 15 g riboflavin and 0 10 ml N,N,N’,N’ tetramethylethylenediamine and irradiated with UV light The yellow block was subsequently comminuted, washed with distilled water and dried In this way antiestriol antibody immobilised in a cross-linked acrylamide homopolymer matrix was obtained.
In addition antiestriol antibody immobilised in an acrylamide copolymer matrix n accordance with the following Table was also prepared.
The cross-reactivity was determined as follows:
Twenty-two mg of dry antiestriol antibody was weighed into small columns and agitated with 0 150 ml of an incubating solution This incubating solution contained SH-estriol and unmarked hapten (estriol, estriol-3-glucuronide or extriol-3-sulfate) The temperature of the reaction was kept constant at O C.
After an incubation period of 30 minutes, the free hapten was separated from the hapten bonded to the antibody by elution with phosphate buffer containing albumin The eluate was collected in on a scintillation glass and diluted with 15 ml of a scintillation liquid and the radioactivity measured in a liquid scintillator The concentration of the free indicator hapten 3 H-estriol was calculated from the impulses.
The results of the determinations in the aqueous system and with the use of polymer matrices of acrylamide homopolymer and acrylamide copolymers are summarised in the following Table The values given are the values of cross reactivity K which is calculated from hundred times the amount of the mass of the corresponding hapten for y = 50, divided by the required mass of the crossreacting hapten for y = 50 The values are calculated on the basis of I Do.
TABLE
Sodium Salt of Sodium Salt of Acrylic Acid/Acrylamide Methacrylic Acid/Acrylamide Aqueous Acrylamide (For indicated Mole Ratio) (For indicated Mole Ratio) System Homopolymer 10:90 30:70 50:50 20:80 40:60 60:40 Estriol-3glucuronide 61 29 19 10 14 14 4 21 Estriol-3sulfate 47 33 30 12 24 27 6 23 The results show that with the use of the copolymers of the invention, a significant increase in bonding specificity was obtained as compared with aqueous systems and acrylamide homopolymers outside this invention.
Through the suitable selection of the copolymer, an increase in specificity by a factor of 15 can be achieved compared with aqueous systems and by a factor of 7 with respect to acrylamide homopolymers This is demonstrated by a comparison of the values of the aqueous system and the acrylamide homopolymer with the 40/60 mole ratio copolymer of methacrylic acid salt and acrylamide.
Example 2.
This Example shows the use of an antibody immobilised in a polymer matrix of the invention in a total determination of thyroxine by the enzymatic hydrolysis with pepsin.
The antibody immobilised in a polymer matrix consisted of an antibody immobilised in a copolymer matrix of acrylamide and 40 mole%, based on the acrylamide, of the sodium salt of methacrylic acid, prepared from a 20 mole% monomer solution and antibody prepared by synthesis of thyroxineethylester and coupling on alubumin on carbodiimide The antibody was produced by the immunisation of rabbits.
Ten l serum with a thyroxine content of 18 lg per 100 ml were diluted with 160 ul of an enzyme solution, said enzyme solution consisting of 2 mg/ml pepsin dissolved in 0.1 N hydrochloric acid.
The enzyme reaction was performed at room temperature in 30 minutes.
To this, 170:ul subsequently 150 pl, of a tracer solution with a content of 5 2 ng/ml of reactively marked thyroxine were added.
The entire solution was then placed on 60 mg antibody gel using the technique of Example 1 The incubation period was 30 minutes, the temperature 22 C.
Evaluation resulted in a recovery of 98 %.
Example 3.
This Example demonstrates the use of an antibody immobilised in a polymer matrix of the invention in the total determination of cortisol.
The antibody immobilised in a polymer OS 1,603,772 S matrix consisted of antibody immobilised in a copolymer matrix of acrylamide and 40 mole /%, based on the acrylamide, of a mixture of sodium and calcium salts of methacrylic acid prepared from a 20 mole% monomer solution and antibody prepared by synthesis of cortisol-C 3-oxime and coupling on albumin; the antibody production being by the immunisation of rabbits.
Ten,id serum or plasma with a cortisol content of 15 ug per 100 ml were prepared.
To this was added 500 AI of a tracer solution consisting of 25 11-cortisol in an aqueous citrate buffer of p H 3 5.
The entire solution was then placed on 100 mg immobilised antibody using the technique of Example 1 The incubation period was 20 minutes, the temperature 25 C.
Evaluation showed a recovery of 99 %.
2 O Example 4.
This Example demonstrates the use of an antibody immobilised in a polymer matrix of the invention in the determination of thyroxine with the application of competitive substances.
The antibody immobilised in a polymer matrix consisted of a copolymer of acrylam:de and 40 mole%, based on the acrylamide, of a mixed calcium-sodium salt of methacrylic acid prepared from a 20 mole% monomer Q O solution and antibody prepared as described in Example 2.
A tracer solution ( 500 Al) consisting of .I-thyroxine in a phosphate buffer at p H 9.6 was placed on 80 mg of the immobilised antibody.
Further, 500 vl of the same tracer solution containing 6 mg/ml anilinenaphtholsulfonic acid, were placed on 80 mg of the immobilised antibody.
Both samples were incubated at a temperature of 22 C for 20 minutes.
Evaluation showed no interference with the bond of thyroxine with the antibody in spite of the high concentration of the competitive substance present, i e anilinenaphtholsulfonic acid.
Claims (4)
WHAT WE CLAIM IS:-
1 An antibody immobilised in a polymer matrix which comprises a matrix of acrylamide copolymer and an antibody immobilised in the matrix, the acrylamide copolymer being a copolymer of acrylamide and at least one monomer chosen from acrylic acid, methacrvlic acid, methacrylamide, salts and esters of acrylic acid or methacrylic acid, acrylamide or methacrylamide substituted at the nitrogen atom, and N,N’dialkyltartardiamides.
2 An antibody immobilised in a polymer matrix according to claim 1 wherein the copolymer is of acrylamide and 20 to 60 mole/%, based on the acrylamide, of methacrylic acid.
3 An antibody immobilised in a polymer matrix according to claim 1 wherein the copolymer is of acrylamide and an alkali metal salt or alkaline earth metal salt of acrylic acid or methacrvlic acid.
4 A process for preparing an antibody immobilised in a polymer matrix which process comprises polymerising acrylamide and at least one monomer as defined in claim 1 in the presence of the antibody to the immobilised.
Antibody immobilised in a polymer matrix prepared by the process claimed in claim 4.
Agents for the Applicants, GALLAFENT & CO, Chartered Patent Agents, 8 Staple Inn, London, WC 1 V 7 QH.
Printed for Her Majesty’s Stationery Office by the Courier Press, Leamington Spa, 1981.
Published by the Patent Office, 25 Southampton Buildings, London, WC 2 A l AY, from which copies may be obtained.
1,663,772
GB16822/78A
1977-05-11
1978-04-27
Antibody immobilized in a acrylamide copolymer matrix
Expired
GB1603772A
(en)
Applications Claiming Priority (1)
Application Number
Priority Date
Filing Date
Title
DE2721267A
DE2721267C2
(en)
1977-05-11
1977-05-11
Antibody gel
Publications (1)
Publication Number
Publication Date
GB1603772A
true
GB1603772A
(en)
1981-11-25
Family
ID=6008655
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
GB16822/78A
Expired
GB1603772A
(en)
1977-05-11
1978-04-27
Antibody immobilized in a acrylamide copolymer matrix
Country Status (24)
Country
Link
US
(1)
US4235867A
(en)
JP
(1)
JPS5417116A
(en)
AT
(1)
AT364856B
(en)
AU
(1)
AU519148B2
(en)
BE
(1)
BE866491A
(en)
BR
(1)
BR7802600A
(en)
CH
(1)
CH637218A5
(en)
DD
(1)
DD136185A5
(en)
DE
(1)
DE2721267C2
(en)
DK
(1)
DK181478A
(en)
ES
(1)
ES469830A1
(en)
FI
(1)
FI781220A
(en)
FR
(1)
FR2390731A1
(en)
GB
(1)
GB1603772A
(en)
GR
(1)
GR64474B
(en)
HU
(1)
HU178485B
(en)
IL
(1)
IL54558A
(en)
LU
(1)
LU79535A1
(en)
NL
(1)
NL7804466A
(en)
NO
(1)
NO781473L
(en)
NZ
(1)
NZ187071A
(en)
PL
(1)
PL121950B1
(en)
SE
(1)
SE7804801L
(en)
ZA
(1)
ZA782358B
(en)
Families Citing this family (13)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
FR2458070A1
(en)
*
1979-05-28
1980-12-26
Compiegne Inst Technol Surf Ac
Nylon gauze strip for determn. of antigens etc. – esp. chagas fever, trypanosoma cruzi, hepatitis B and progesterone in blood serum
WO1981002343A1
(en)
*
1980-02-05
1981-08-20
Japan Atomic Energy Res Inst
Unit system for use in medical analysis and process for preparing same
JPS5729949A
(en)
*
1980-07-30
1982-02-18
Nippon Koutai Kenkyusho:Kk
Determination of sugar branch related to cancer and diagnostic technique of cancer
US4540660A
(en)
*
1983-04-07
1985-09-10
Daryl Laboratories, Inc.
Substrate for fluoroimmunoassay of biological fluids
JPS61228351A
(en)
*
1985-04-02
1986-10-11
Kyoto Ikagaku Kenkyusho:Kk
Method for detecting hemoglobin in excretion
AU7309487A
(en)
*
1986-04-30
1987-11-24
Baylor College Of Medicine
Polyamide resin and method for preparation of reagents for immunodiagnostic use
DE3921498A1
(en)
*
1988-09-28
1990-03-29
Bayer Ag
POLYMER-TIED DYES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5262297A
(en)
*
1990-06-18
1993-11-16
Eastman Kodak Company
Specific binding analytical and separation methods using carboxy containing polymers
US5147777A
(en)
*
1990-06-18
1992-09-15
Eastman Kodak Company
Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use
US5149737A
(en)
*
1990-06-18
1992-09-22
Eastman Kodak Company
Carboxy containing monomers and polymers and latices prepared from same
US5210289A
(en)
*
1990-06-18
1993-05-11
Eastman Kodak Company
Carboxy containing monomers
US5424219A
(en)
*
1991-10-25
1995-06-13
Cytech Biomedical, Inc.
Method of performing assays for biomolecules and solid supports for use in such methods
EP2192409B1
(en)
*
2008-11-26
2014-04-23
Corning Incorporated
Label independent detection biosensor composition and methods thereof
Family Cites Families (2)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US3925017A
(en)
*
1973-05-01
1975-12-09
Wisconsin Alumni Res Found
Preparation of dry, porous gel particles having high water regain for liquid sampling
US4061466A
(en)
*
1974-10-16
1977-12-06
Ingvar Gosta Holger Sjoholm
Biologically active composition and the use thereof
1977
1977-05-11
DE
DE2721267A
patent/DE2721267C2/en
not_active
Expired
1978
1978-04-19
GR
GR56025A
patent/GR64474B/en
unknown
1978-04-20
IL
IL54558A
patent/IL54558A/en
unknown
1978-04-20
FI
FI781220A
patent/FI781220A/en
not_active
Application Discontinuation
1978-04-21
AU
AU35364/78A
patent/AU519148B2/en
not_active
Expired
1978-04-24
US
US05/899,744
patent/US4235867A/en
not_active
Expired – Lifetime
1978-04-24
AT
AT0290978A
patent/AT364856B/en
not_active
IP Right Cessation
1978-04-25
ZA
ZA00782358A
patent/ZA782358B/en
unknown
1978-04-26
NZ
NZ187071A
patent/NZ187071A/en
unknown
1978-04-26
CH
CH454178A
patent/CH637218A5/en
not_active
IP Right Cessation
1978-04-26
LU
LU79535A
patent/LU79535A1/en
unknown
1978-04-26
DK
DK181478A
patent/DK181478A/en
not_active
Application Discontinuation
1978-04-26
BR
BR7802600A
patent/BR7802600A/en
unknown
1978-04-26
NL
NL7804466A
patent/NL7804466A/en
not_active
Application Discontinuation
1978-04-26
FR
FR7812344A
patent/FR2390731A1/en
active
Granted
1978-04-26
NO
NO78781473A
patent/NO781473L/en
unknown
1978-04-26
SE
SE7804801A
patent/SE7804801L/en
unknown
1978-04-27
GB
GB16822/78A
patent/GB1603772A/en
not_active
Expired
1978-04-27
HU
HU78CA424A
patent/HU178485B/en
unknown
1978-04-27
JP
JP5072678A
patent/JPS5417116A/en
active
Granted
1978-04-27
ES
ES469830A
patent/ES469830A1/en
not_active
Expired
1978-04-27
PL
PL1978206415A
patent/PL121950B1/en
unknown
1978-04-27
DD
DD78205046A
patent/DD136185A5/en
unknown
1978-04-27
BE
BE187209A
patent/BE866491A/en
not_active
IP Right Cessation
Also Published As
Publication number
Publication date
DE2721267C2
(en)
1985-05-02
DK181478A
(en)
1978-11-12
US4235867A
(en)
1980-11-25
NZ187071A
(en)
1980-12-19
BR7802600A
(en)
1979-01-23
FI781220A
(en)
1978-11-12
AT364856B
(en)
1981-11-25
JPS5417116A
(en)
1979-02-08
DD136185A5
(en)
1979-06-20
IL54558A0
(en)
1978-07-31
FR2390731A1
(en)
1978-12-08
HU178485B
(en)
1982-05-28
AU3536478A
(en)
1979-10-25
JPS6229747B2
(en)
1987-06-27
CH637218A5
(en)
1983-07-15
LU79535A1
(en)
1978-09-29
NO781473L
(en)
1978-11-14
FR2390731B1
(en)
1984-05-04
PL121950B1
(en)
1982-06-30
NL7804466A
(en)
1978-11-14
ATA290978A
(en)
1981-04-15
BE866491A
(en)
1978-08-14
PL206415A1
(en)
1980-11-17
AU519148B2
(en)
1981-11-12
IL54558A
(en)
1982-01-31
GR64474B
(en)
1980-03-27
DE2721267A1
(en)
1978-11-23
ZA782358B
(en)
1979-04-25
ES469830A1
(en)
1978-12-16
SE7804801L
(en)
1978-11-12
Similar Documents
Publication
Publication Date
Title
US4048298A
(en)
1977-09-13
Solid phase double-antibody radioimmunoassay procedure
GB1603772A
(en)
1981-11-25
Antibody immobilized in a acrylamide copolymer matrix
US5168057A
(en)
1992-12-01
Trifunctional conjugates
JPS5896616A
(en)
1983-06-08
Latex, biologically active latex conjugate and manufacture
JPH0737988B2
(en)
1995-04-26
Ion capture immunoassay method and device
DK165381B
(en)
1992-11-16
IMMUNO ANALYSIS FOR THE DETERMINATION OF LIGANDS BY BIOTIN AND ANTIBIOTIN
EP0321261A1
(en)
1989-06-21
Use of immobilized biotinylated receptor in test device, kit and method for determining a ligand
US4256724A
(en)
1981-03-17
Method for non-covalent coating of antibodies on solid substrates
US4235865A
(en)
1980-11-25
Method for the determination of unbound hormones and pharmaceuticals
AU609721B2
(en)
1991-05-09
Dispersion polymers, biologically active dispersion polymers, a process for their preparation, and their use as diagnostic aids
EP0270937B1
(en)
1992-09-23
Stable immobilized hapten reagent for use in heterogeneous immunometric assays
GB1575998A
(en)
1980-10-01
Extraction-free cortisol assay
JPH05310849A
(en)
1993-11-22
Multifunctional, hydrophilic, spherical microparticle preparation and use thereof
GB2260609A
(en)
1993-04-21
A separation method employing precursor species
Chase et al.
1976
Quantitation of cannabinoids in biological fluids by radioimmunoassay
PL110972B1
(en)
1980-08-30
Method of determination of hormones or drugs total content
Levine et al.
1973
Levels of 13, 14-dihydro-15-keto-PGF2α in biological fluids as measured by radioimmunoassay
JP2579972B2
(en)
1997-02-12
Membrane affinity concentrated immunoassay
JPH02194360A
(en)
1990-07-31
Immunochemical testing agent containing polymer containing carboxyl group
US4652532A
(en)
1987-03-24
Free radical based biochemical method for detecting substances in fluids
US3972992A
(en)
1976-08-03
Diagnostic test for opium alkaloids
JP2947600B2
(en)
1999-09-13
Immunoassay
JPH0854393A
(en)
1996-02-27
Specific bonding method and test kit
AU595899B2
(en)
1990-04-12
Method for diagnostic immunoassay by solid phase separation
CA1143653A
(en)
1983-03-29
Hapten bound to carboxyl containing water-soluble mono-olefinic polmeric compound
Legal Events
Date
Code
Title
Description
1982-02-17
PS
Patent sealed [section 19, patents act 1949]
1986-01-08
PCNP
Patent ceased through non-payment of renewal fee
